Alkem Laboratories Limited — Q3 FY26
Alkem Laboratories reported Q3 FY26 revenue of ₹3,737 crore (+10.7% YoY) and EBITDA of ₹828 crore (+9% YoY), with EBITDA margin at 22.2%.
bullish
high
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q2 FY26
India business to outperform IPM by 100-150 bps
Management expects India growth to continue at double-digit, outperforming IPM by 100-150 bps in H2 FY26 and FY27.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1